METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
Hypothesis: Patients with metastatic colorectal cancer with DNA mismatch repair-proficient
(pMMR) function / microsatellite-stable (MSS) phenotype harbor a non-immunogenic disease that
can be transformed into an immunogenic condition by short-course oxaliplatin-based therapy,
and may achieve durable disease control or even tumor eradication by the addition of immune
checkpoint blockade therapy to the standard-of-care oxaliplatin-based treatment.